Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Aug 23;11:5121–5132. doi: 10.2147/OTT.S167868

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Zhou et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

A Chou-Talalay analysis demonstrated that SG611-PDCD5 and low-dose daunorubicin have a synergistically anti-proliferative effect on various leukemic cell lines.

Notes: The effects of the various treatments are demonstrated on (A) K562, (B) MEG-01, (C) KG-1a, (D) HL-60, (E) BV-173, and (F) SUP-B15 cells, respectively. As shown in (A), the CI<1 when the proliferative inhibition ratio was >0.50, suggesting a synergistic effect on K562 cells under these conditions. ED50, ED75, and ED90 referred to the dose when the fractional effect was 0.50, 0.75, and 0.90, respectively.

Abbreviation: CI, combination index.

A Chou-Talalay analysis demonstrated that SG611-PDCD5 and low-dose daunorubicin have a synergistically anti-proliferative effect on various leukemic cell lines.

Notes: The effects of the various treatments are demonstrated on (A) K562, (B) MEG-01, (C) KG-1a, (D) HL-60, (E) BV-173, and (F) SUP-B15 cells, respectively. As shown in (A), the CI<1 when the proliferative inhibition ratio was >0.50, suggesting a synergistic effect on K562 cells under these conditions. ED50, ED75, and ED90 referred to the dose when the fractional effect was 0.50, 0.75, and 0.90, respectively.

Abbreviation: CI, combination index.